Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth +22 more·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 301–400 of 1,013

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis
Yin Wang, Yanqing Li, Ye Chai · 2021 · Journal of International Medical Research
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Raleigh Ayoolu Fatoki, Kelly Koehn, Amar Harry Kelkar, Samer Al Hadidi, Nikita Mehra, Hira S. Mian, Ola Landgren, Dickran Gano Kazandjian, James Edward Hoffman, Douglas Weston Sborov et al. · 2022 · JCO Global Oncology
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
Issam S. Hamadeh, Emily S. Reese, Justin R. Arnall, Ekaterina Kachur, Allison L. Martin, Meghan Schneider, Reed N. Friend, Barry A. Paul, Shebli Atrash, Manisha Bhutani et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents
Shuku Sato, Wataru Kamata, Satomi Okada · 2020 · International Journal of Hematology
Chemotherapy-based regimens in multiple myeloma in 2020
Massimo Gentile, Fortunato Morabito, Massimo Vincenzo Martino, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper
Shakira Jeanene Grant, Hira S. Mian, Smith Giri, Mélina Boutin, Lorenzo Dottorini, Nina Rosa Neuendorff, Jessica L. Krok‐Schoen, Nikita Nikita, Ashley Elizabeth Rosko, Tanya Marya Wildes et al. · 2020 · Journal of Geriatric Oncology
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
Issam S. Hamadeh, Donald C. Moore, Allison L. Martin, Allison Karabinos, Hailey Hill, Ami P Ndiaye, Jordan Robinson, Barry A. Paul, Shebli Atrash, Manisha Bhutani et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
Simone A. Minnie, Geoffrey R. Hill · 2021 · Frontiers in Immunology
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials
Jiasheng Wang, Changsu Park, Raul Arroyo-Suárez · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
Hedwig M. Blommestein, Margreet G. Franken, Chrissy H.Y. van Beurden-Tan, Nicole M. A. Blijlevens, Peter C. Huijgens, Pieter Sonneveld, Carin A. Uyl‐de Groot, Sonja Zweegman · 2021 · JAMA Network Open
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Radowan A. Elnair, Sarah A. Holstein · 2021 · Drugs
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
Cecilie Hveding Blimark, Annette Juul Vangsted, Tobias Wirenfeldt Klausen, Henrik Gregersen, Agoston Gyula Szabo, Emil Hermansen, Göran Wålinder, Dorota Knut‐Bojanowska, Chenyang Zang, Ingemar Turesson et al. · 2021 · European Journal Of Haematology
Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
Kazuhito Suzuki, Kaichi Nishiwaki, Shingo Yano · 2021 · Cancers
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Susanne Ghandili, Katja Christina Weisel, Carsten Bokemeyer, Lisa Beatrice Leypoldt · 2021 · Oncology Research and Treatment
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations
Justin R. Arnall, Kathryn T. Maples, Robert Donald Harvey, Donald C. Moore · 2021 · Annals of Pharmacotherapy
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
Ivana Lagreca, Giovanni Riva, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Francesca Bettelli, Davide Giusti, Angela Cuoghi, Paola Bresciani et al. · 2022 · International Journal of Molecular Sciences
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Maarten R. Seefat, David G. J. Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman, Hedwig M. Blommestein · 2021 · Cancers
Moving Toward a Cure for Myeloma
María‐Victoria Mateos, Ajay K. Nooka, Sarah Marie Larson · 2022 · American Society of Clinical Oncology Educational Book
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
Mark Sellin, Stephanie A Berg, Patrick Alan Hagen, Jiwang Zhang · 2022 · Translational Oncology
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodríguez‐Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando et al. · 2022 · Hematological Oncology
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
María‐Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Špıčka, Rik Schots, Tomasz Wróbel, Gordon Cook, Meral Beksaç, Katharine S. Gries, Anupa Kudva et al. · 2022 · Journal of Oncology Pharmacy Practice
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
Weijun Fu, Wei Li, Jianda Hu, Gang An, Yafei Wang, Chengcheng Fu, Lijuan Chen, Jie Jin, Xinan Cen, Zheng Ge et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
Mateo Mejía Saldarriaga, Walaa Darwiche, David S. Jayabalan, Jorge Monge, Cara Ann Rosenbaum, Roger Niles Pearse, Rubén Niesvizky, Mark W. Bustoros · 2022 · Frontiers in Oncology
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Munawwar Hussain, Sarvari Venkata Yellapragada, Samer Al Hadidi · 2023 · Blood and Lymphatic Cancer Targets and Therapy
Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies
Hannah Victoria Giles, Kamaraj Karunanithi · 2024 · Antibodies
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Frida Bugge Askeland, Einar Haukås, Tobias Schmidt Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Liv Osnes, Anna Lysén, Pegah Abdollahi, Lene Kongsgaard Nielsen, Emil Hermansen et al. · 2025 · The Lancet Haematology
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
Susan Bal, Allison Weaver, Robert Frank Cornell, Luciano J. Costa · 2019 · British Journal of Haematology
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
Kohmei Kubo, Mitsuo Hori, Kensuke Ohta, Hiroshi Handa, Kiyohiko Hatake, Morio Matsumoto, Shotaro Hagiwara, Kazuteru Ohashi, Chiaki Nakaseko, Kenshi Suzuki et al. · 2019 · International Journal of Hematology
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
Benedetta Dalla Palma, Valentina Marchica, Maria Teresa Catarozzo, Nicola Giuliani, Fabrizio Accardi · 2020 · Journal of Clinical Medicine
Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
Francesca Bonello, Mario Boccadoro, Alessandra Larocca · 2020 · Cancers
Risk and Response-Adapted Treatment in Multiple Myeloma
Titouan Cazaubiel, Olga Mulas, Lydia Montes, Anaïs Schavgoulidze, Hervé Avet‐Loiseau, Jill Corre, Aurore Perrot · 2020 · Cancers
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2022 · Cancers
Flexibly coupled multiprocessors for image processing
Myung Hoon Sunwoo, J.K. Aggarwal · 1990 · Journal of Parallel and Distributed Computing
Kidney disease in multiple myeloma
Frank Bridoux, Nelson Leung, Samih H. Nasr, Arnaud Jaccard, Virginie Royal · 2024 · La Presse Médicale
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
E. Bridget Kim, Jack E. Malespini, Matthew M. Lei, Samuel S. Han, Cole Minsky, Andrew Robert Branagan, Elizabeth O’Donnell, Diana D. Cirstea, Noopur S Raje, Andrew Jenho Yee · 2025 · Blood Advances
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andréa Capra et al. · 2020 · Haematologica
Treatment of older adult or frail patients with multiple myeloma
Shakira Jeanene Grant, Ciara Louise L. Freeman, Ashley Elizabeth Rosko · 2021 · Hematology
Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells
Ryan P. Staupe, Kenneth E. Lodge, Nithya Thambi, David Toole, Alex M. Tamburino, Dan Chang, Bonnie J. Howell, Daria J. Hazuda, Kalpit A. Vora, Nicole Sullivan · 2022 · Communications Biology
Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis
Joseph Ficek, Eleftheria Kalaitzaki, Shuai Sammy Yuan, Alessandra Tosolini, Ling Du, Brandon Edward Kremer, Katherine Davy, Helen Zhou, Tai‐Tsang Chen · 2023 · Clinical Lymphoma Myeloma & Leukemia
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Kazimierz Groen, Claudia A.M. Stege, Kazem Nasserinejad et al. · 2023 · EClinicalMedicine
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
Qaiser Bashir, Kamal Chamoun, Denái R. Milton, Maliha Khan, Sairah Ahmed, Rohtesh S. Mehta, Uday Popat, Partow Kebriaei, Yago L. Nieto, Betül Oran et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Subhashis Sarkar, Sachin Kumar Singh Chauhan, John M. Daly, Alessandro Natoni, Heather E. Fairfield, Robert B. Henderson, Emma Nolan, Dawn Swan, Jinsong Hu, Michaela Ruth Reagan et al. · 2020 · Cancer Immunology Immunotherapy
Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis
Jiasheng Wang, Yeseong D. Kim · 2020 · International Journal of Hematology
Novel strategies to target the humoral alloimmune response
Ondřej Suchánek, Menna Ruth Clatworthy · 2020 · HLA
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
Alessandro Gozzetti, Francesca Bacchiarri, Vincenzo Sammartano et al. · 2020 · Frontiers in Oncology
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Francesca Bonello, Mariella Grasso, Mattia D’Agostino, Ivana Celeghini, Alessia Castellino, Mario Boccadoro, Sara Bringhen · 2020 · Pharmaceuticals
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
Larysa Jessica Sanchez, Joshua Ryan Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari · 2021 · Therapeutic Advances in Hematology
Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma
Takashi Watanabe · 2021 · Cancers
Proteomics-inspired precision medicine for treating and understanding multiple myeloma
Matthew Ho, Giada Bianchi, Kenneth Carl Anderson · 2020 · Expert Review of Precision Medicine and Drug Development
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Ruolan Xia, Yuan Cheng, Xuejiao Han, Yuquan Wei, Xiawei Wei · 2021 · Frontiers in Molecular Biosciences
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Lucio Gordan, Carlyn Rose C. Tan, Robert Allen Vescio et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Dorothea Hose, Martin Schreder, Jochen Hefner, Max Bittrich, Sophia Danhof, Susanne Strifler, Maria‐Theresa Krauth, Renate Schoder, Bettina Gisslinger, Hermann Einsele et al. · 2020 · Journal of Cancer Research and Clinical Oncology
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome
Marcella Kaddoura, Moritz Binder, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie Abraham Gertz, Angela A. Dispenzieri, Prashant Kapoor, Yi L. Hwa, Amie L Fonder et al. · 2022 · American Journal of Hematology
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei Sun, Yin-Ting Wong, Ka Man Cheung, Carmen Michelle Yuen, Yun-Tat Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum Fan, Yuen-Kiu Chow, Man Fai Law et al. · 2022 · Diagnostics
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
Francesca Bonello, Serena Rocchi, Gregorio Barilà et al. · 2022 · Frontiers in Oncology
Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom
Mohamad Mohty, Wolfgang Ulrich Knauf, Dorothy Romanus, Shelby L. Corman, Katharina Verleger, Youngmin Kwon, Dasha Cherepanov, M. Janelle Cambron‐Mellott, Haris G. Vikis, Francisco Gonzalez et al. · 2020 · European Journal Of Haematology
Monoclonal antibodies in multiple myeloma
Federico Vozella, Francesca Fazio, Gianfranco Lapietra, Maria Teresa Petrucci, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
Takeshi Yoroidaka, Kentaro Narita, Hiroyuki Takamatsu · 2021 · Scientific Reports
Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma
Yulu Yang, Rui Chen, Yi Gong · 2022 · Biomaterials
Immunomodulatory Agents for Multiple Myeloma
Jiří Minařík, Sabina Ševčı́ková · 2022 · Cancers
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Philippe Moreau, Thierry T.F. Facon, Saad Z. Usmani, Nizar Jacques Bahlis, Noopur S Raje, Torben Plesner, Robert Zygmunt Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin et al. · 2025 · Leukemia
New Strategies for the Treatment of Older Myeloma Patients
Alessandra Larocca, Lorenzo Cani, Giuseppe Bertuglia, Benedetto Bruno, Sara Bringhen · 2023 · Cancers
Tunable polymeric micelles for taxane and corticosteroid co-delivery
Armin Azadkhah Shalmani, Alec Wang, Zaheer Ahmed, Maryam Sheybanifard, Rahaf Mihyar, Eva Miriam Buhl, Michael Pohl, Wim E. Hennink, Fabian M. Kiessling, Josbert M. Metselaar et al. · 2023 · Drug Delivery and Translational Research
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Niels W.C.J. van de Donk, Sonja Zweegman · 2023 · Hematology/Oncology Clinics of North America
Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
Tu Ngoc Nguyen, Fahed Ahmad, Richard I. Lindley · 2024 · British Journal of Clinical Pharmacology
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Emiliano Barbieri, Enrica Antonia Martino, Elena Rivolti, Micol Quaresima, Ernesto Vigna, Antonino Neri, Fortunato Morabito, Massimo Gentile · 2024 · Expert Opinion on Biological Therapy
Network meta‐analysis of first‐line treatments in transplant‐ineligible multiple myeloma patients
Manuel David Gil‐Sierra, Vicente Gimeno‐Ballester, Silvia Fenix-Caballero, Emilio Jesús Alegre Del Rey · 2020 · European Journal Of Haematology
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
Meral Beksaç, Yıldız Aydın, Hakan Göker, Mehmet Turgut, Sevgi Kalayoğlu Beşışık, Seçkin Çağırgan, Tülin Tuğlular, Filiz Vural, Münci Yağcı, İnci Alacacıoğlu et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database
Victor Hugo Jimenez-Zepeda, Christopher Paul Venner, Arleigh B. Robertson McCurdy, Esther Masih‐Khan, Eshetu G. Atenafu, Michaël Sébag, Julie Stakiw, Kevin Song, Richard LeBlanc, Tony Reiman et al. · 2021 · British Journal of Haematology
Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina D. Shah, Joshua Ryan Richter, David H. Vesole, Sandy Wai Kuan Wong, Chiung‐Yu Huang, Deepu Madduri, Sundar Jagannath, David Samuel DiCapua Siegel, Noa Biran et al. · 2021 · Cancer
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
Luca Julius Pape, Julia Hambach, Anna Josephine Gebhardt, Björn Rissiek, Tobias Stähler, Natalie Tode, Cerusch Khan, Katja Christina Weisel, Gerhard Adam, Friedrich Koch‐Nolte et al. · 2022 · Frontiers in Immunology
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents
Pamela Becherini, Debora Soncini, Silvia Ravera, Elisa Gelli, Claudia Martinuzzi, Giulia Giorgetti, Antonia Cagnetta, Fabio Guolo, Federico Ivaldi, Maurizio Miglino et al. · 2023 · Antioxidants
More intensive therapy has a better effect for frail parents with multiple myeloma
Clark DuMontier, Jennifer La, John R. Bihn, June Corrigan, Cenk Yildirim, Mayuri Dharne, Hamza Hassan, Sarvari Venkata Yellapragada, Gregory Alan Abel, J. Michael Gaziano et al. · 2023 · Blood Advances
Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers
Lorenzo Pradelli, Massimo Massaia, Elisabetta Todisco, Filíppo Gherlinzoni, Anna Furlan, Maria Luisa Latargia, Elisabetta Grande, Ezio Tripoli, Francesca Occhipinti, Francesco Comello et al. · 2023 · Cancer Medicine
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Andrew G Spencer, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark‐David Levin, Pieter Sonneveld, Robert Zygmunt Orlowski, Sung‐Soo Yoon, Saad Z. Usmani et al. · 2023 · Blood Advances
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Alissa Visram, A. De La Torre, Darrell J. White et al. · 2023 · Blood Cancer Journal
Beyond BCMA: newer immune targets in myeloma
Melinda Si Yun Tan, Yunxin Chen, Eric L. Smith · 2024 · Blood Advances
LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway
Li Xie, Chiqi Chen, Tinghua Zhang, Wenqian Yang, Denghao Zheng, Liyuan Cao, Jin Yuan, Yilu Xu, Yaping Zhang, Ligen Liu et al. · 2024 · Cell Death and Disease
Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting
Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos · 2020 · Clinical Lymphoma Myeloma & Leukemia
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review
Larysa Jessica Sanchez, Kevin M. Barley, Joshua Ryan Richter, Joseph K. Franz, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Ajai Chari · 2020 · Expert Review of Hematology
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
In Gyu Hwang, Minsuk Kwon, Jin Won Kim, Se Hyun Kim, Yun‐Gyoo Lee, Jin Young Kim, Su‐Jin Koh, Yoon Ho Ko, Seong Hoon Shin, Soojung Hong et al. · 2021 · Cancers
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Marc Justin Braunstein, Jonathan Weltz, Faith E. Davies · 2021 · Expert Review of Hematology
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Andrzej J. Jakubowiak, Saad Z. Usmani, Amrita Y. Krishnan, Sagar Lonial, Raymond L. Comenzo, Jianping Wang, Carla de Boer, William M Deraedt, Brendan M. Weiss, Jordan Mark Schecter et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
Nurulhuda Binte Mustafa, Adina Huey Fang Nee, Jing-Yuan Chooi, Sabrina Hui Min Toh, Tae‐Hoon Chung, Viknesvaran Selvarajan, Shuangyi Fan, Siok‐Bian Ng, Michelle Poon, Esther Hian Li Chan et al. · 2021 · Journal for ImmunoTherapy of Cancer
Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications
Jaqueline Schütt, Theresa Maria Nägler, Tino Schenk, Annamaria Brioli · 2021 · Cancers
COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
Mansi R. Shah, Alissa Gabel, Stephanie Beers, Gratian Salaru, Yong Lin, DENNIS L. COOPER · 2021 · Clinical Lymphoma Myeloma & Leukemia
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database
Hira S. Mian, Donna Ellen Reece, Esther Masih‐Khan, Arleigh B. Robertson McCurdy, Moustafa Kardjadj, Victor Hugo Jimenez-Zepeda, Kevin Song, Martha Louzada, Richard LeBlanc, Michaël Sébag et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
Moving Toward Continuous Therapy in Multiple Myeloma
Francesca Bonello, Giusy Cetani, Luca Bertamini, Francesca Gay, Alessandra Larocca · 2019 · Clinical Hematology International
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, Noriko Fukuhara, Sachiko Seo, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura et al. · 2020 · British Journal of Haematology
Antibody-Based Treatment Approaches in Multiple Myeloma
Hitomi Hosoya, Surbhi Sidana · 2021 · Current Hematologic Malignancy Reports
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Albert Oriol, Laura Abril, Anna Torrent, Gladys Ibarra, Josep‐María Ribera · 2021 · Therapeutic Advances in Hematology
Drug resistance and minimal residual disease in multiple myeloma
Alessandro Gozzetti, Sara Ciofini, Anna Sicuranza, Paola Pacelli, Donatella Raspadori, Emanuele Cencini, Dania Tocci, Monica Bocchia · 2022 · Cancer Drug Resistance
In vitro assays and development strategies for magnesium-based biodegradable cardiovascular stent: A decade of review
Jiaqi Xu, Jiawei Zou, Dianyi Zhang, Kaili Zhang, Yining Qi, Changwen Yan, Eui‐Seok Lee, Qi Jia, Chen Ma, Heng Bo Jiang · 2025 · Progress in Materials Science
Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico
Jorge Vela‐Ojeda, David Gómez‐Almaguer, Ramiro Espinoza-Zamora et al. · 2021 · Archives of Medical Research
Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma
Margaux Lejeune, Murat Cem Köse, Mégane Jassin, Marie‐Jia Gou, Amaury Herbet, Elodie Duray, Gaël Cobraiville, Jacques Foguenne, Didier Boquet, André Gothot et al. · 2023 · HemaSphere
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
Peter H. Langer, Lukas John, Ina Monsef · 2024 · Cochrane Database of Systematic Reviews
Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties
Heleen Hanssens, Fien Meeus, Emma Gesquiere, Janik Puttemans, Yannick De Vlaeminck, Kim De Veirman, Karine Breckpot, Nick Devoogdt · 2024 · International Journal of Molecular Sciences
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Rahul Kumar Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron Seth Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Angela A. Dispenzieri, Sagar Lonial, Brian G. M. Durie et al. · 2024 · Blood
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Sarah Mettias, Adam ElSayed, Jonathan Moore, James R. Berenson · 2025 · Targeted Oncology
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients
Faouzi Djebbari, Faye Amelia Sharpley, Susan McLain-Smith, Grant D. Vallance, Toby Andrew Eyre, Jaimal Kothari, Sally E. Moore, Karthik Ramasamy · 2020 · PLoS ONE